Prognosis in the Cases With Renal Cell Carcinoma According to Clinical Parameters

Fukuda, M; Satomi, Yoshiaki; Asakura, Takeshi; Hosaka, Masahiko; Noguchi, Sumio; Kishida, Takeshi; Kondou, I; Ida, Tokio; Hirokawa, Makoto; Kumagai, Harumi; Shiozaki, Hiroshi; Ishizuka, Eiichi; Miyai, Keikoku; Fukuoka, Hiroshi; Sasaki, Kouichi; Oogo, Yoshiharu; Koudaira, Teruo; Ogawa, Katuaki; Nakahashi, Mitsuru; Matsuura, K.; Moriyama, Masatoshi; Udagawa, Kouichi; Sugita, Y.; Ishibashi, Yoshio; Shimura, Hidetoshi

doi:10.5980/jpnjurol1989.89.647

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall 5-year survival rate is reported 44-56%, and 10-year survival is 30-38% [18][19]. Regional recurrence or metastasis can occur even in Stage I or II cases and over 5 years after tumor resection [4,19]. A much more favorable outcome is expected in young patients, especially those under 10 years of age [3][4][5][6][7][8]12].…”

Section: Discussionmentioning

confidence: 99%

“…Two staging systems are mainly used, the Robson [26] and pTNM [18] systems. Overall 5-year survival rate is reported 44-56%, and 10-year survival is 30-38% [18][19]. Regional recurrence or metastasis can occur even in Stage I or II cases and over 5 years after tumor resection [4,19].…”

Section: Discussionmentioning

confidence: 99%

“…Accurate staging is determined by histologic examination of the regional lymph node. Lymphadenectomy is considered effective for pediatric patients to prevent recurrence or metastasis, because risk of nodal involvement is generally higher in children than in adults [4,18] and patients with lymph node involvement have a significantly increased risk of developing distant metastases and a relatively increased risk of local recurrence [3,11,[18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

“…Though prognostic factors include patient age [3,4], tumor size [18,19], histologic pattern [6,9], vascular invasion [1,2,6], or chromosomal abnormality [14,15], the most important prognostic determinator is anatomical extent of the tumor, i.e., pathologic stage [2][3][4][5][6][7][8][13][14][15][16][17][18][19]. Two staging systems are mainly used, the Robson [26] and pTNM [18] systems.…”

Section: Discussionmentioning

confidence: 99%

“…We report two cases of advanced pediatric RCC with lymph node involvement that were treated by nephrectomy with lymphadenectomy followed by interferon-␣ (IFN: human lymphoblastoid interferon, Sumipheron) injection. We discuss the treatment of pediatric RCC compared to that of adults [18][19][20][21] as well as the use of IFN for treating advanced pediatric RCC [22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of childhood renal cell carcinoma with lymph node metastasis: Two cases and a review of literature

Uchiyama¹,

Iwafuchi²,

Yagi³

et al. 2000

J. Surg. Oncol.

View full text Add to dashboard Cite

Standard treatment for renal cell carcinoma (RCC) is radical nephrectomy with lymph node dissection. Stages I and II have encouraging prognoses, but Stage III with regional lymph node metastasis can be unfavorable. Adjuvant therapy for pediatric patients with advanced RCC with lymph node involvement or metastatic lesion has not been defined. Advanced pediatric RCC is reported in two patients (boys, aged 6 and 9 years: Stage IIIs, Robson; Stage III and IV, pTNM classification) treated by nephrectomy and lymph node dissection followed by postoperative interferon-alpha (IFN), that can be used as an adjuvant therapy with side effects such as fever, bone marrow suppression, or decreased liver function. One is doing well for 7 years, another is suffered from lung metastases at 3 years after surgery. Although immunotherapy is expected to improve survival in pediatric patients with advanced RCC, surgical resection of renal and metastatic tumors remains the standard treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of childhood renal cell carcinoma with lymph node metastasis: Two cases and a review of literature

Uchiyama¹,

Iwafuchi²,

Yagi³

et al. 2000

J. Surg. Oncol.

View full text Add to dashboard Cite

show abstract

Lung Resistance-Related Protein

Kazue¹,

Toshiko²,

H-Y³

et al. 2017

Encyclopedia of Cancer

View full text Add to dashboard Cite

Abstract. A large number of renal cancer patients show poor or partial response to chemotherapy and the precise mechanism has not been understood yet. MDR is the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs and is associated with the elevated expression of MDR proteins. These are divided into two groups: ABC transporters and non-ABC transporters. The aim of our study was to determine the expression of MDR1/Pgp, MRP1 and LRP in 47 samples of renal cell carcinomas using immunohistochemical assay. Our results were analysed in relation to nuclear grade and other clinical and pathological parameters to see the possible correlation between the expression of MDR proteins and factors mentioned above. The majority of renal carcinoma specimens showed positivity for MDR proteins. In this regard, 21 % of samples revealed positive results for MDR1, 62 % for MRP1 and 76.6 % for LRP protein. Furthermore, our study displayed significant differences between MDR1, LRP and nuclear grade. On the other hand, no association was found between MRP1 and nuclear grade, as well as between the expression of three MDR proteins and other clinically relevant parameters.

show abstract

Is oncologic surgery in a low-volume district general hospital justified? A critical 24-year audit

Szecsi¹

2004

Eur Surg

View full text Add to dashboard Cite

Darf onkologische Chirurgie an regionalen Standardkrankenhäusern vorgenommen werden? Eine kritische 24-Jahres-Bilanz Zusammenfassung. Grundlagen: Eine aktuelle Diskussion thematisiert die Zentralisation onkologischer Chirurgie sowie die Auswirkungen chirurgischer und institutioneller Fallzahlen auf die Ergebnisse, -wobei onkologische Eingriffe an Standardkrankenhäusern mit geringer Fallzahl infragegestellt werden. Methodik: Die Daten von 543 operierten onkologischen Patienten des Zeitraumes 03/78 bis 12/2001 wurden in ein Register eingebracht. Endpunkte waren 30-Tage-Letalität sowie die Rate lokoregionärer Rezidive, des Gesamtüber-lebens, tumorspezifischen Überlebens von Entitätsgruppen und UICC-Stadien sowie krankheitsfreien Überlebens. Die Daten wurden durch Referenzzahlen validiert.Ergebnisse: Nach Abzug von Patienten mit prozeduralem Minimalrisiko betrug die 30-Tage Letalität 11 %, -8,1 % nach Elektiveingriffen und 8 % nach R0-Resektionen. Die Letalität durch chirurgische Komplikationen betrug 0,7 % bzw. 0,8 % und 0,3 %, die Letalität durch Allgemeinkomplikationen 10,3 % (5,1 % kardial, 2,0 % pulmonal und 3,2 % andere) bzw. 7,2 % und 7,6 %. Lokalrezidiv-, Gesamtüberlebens-, tumorspezifische Überlebens-und krankheitsfreie Überlebensraten waren gut bis exzellent.Schlussfolgerungen: Chirurgische Kompetenz konnte in einem Regionalspital mit niedriger Fallzahl aufrechterhalten werden. Die Ergebnisse wurden jedoch durch eine vergleichsweise hohe Letalität infolge Allgemeinkomplikationen beeinträchtigt, was die Bedeutung von Risikoevaluierung und institutioneller interdisziplinärer Infrastruktur unterstreicht. Es bietet sich somit eine Strategie selektiver Zentralisation an. Häufige onkologische Erkrankungen mit akzeptabler Begleitmorbidität können mit gleichwertigen Ergebnissen an Regionalspitälern behandelt werden, die sich somit für ihre Integration in den Verbund kooperierender virtueller Regionalzentren qualifizieren.Schlüsselwörter: Onkologische Chirurgie, "low volume"-Krankenhäuser, chirurgische Ergebnisqualität, 30-Tage Letalität, Strukturqualität.Summary. Background: An ongoing discussion focusses on centralization of oncologic surgery and effects of surgical and institutional volumes on outcome, -questioning if oncologic surgery in low volume district general hospitals is justified.Methods: Data of 543 patients undergoing surgery for various cancer entities from 03/1978 until 12/2001 were entered in a prospectively maintained database. Endpoints were 30-day mortality (30 DM), the rate of locoregional recurrence (LR), overall survival (OAS), cause-specific survival (CSS) of entity-and UICC-stage-groups and disease-free survival (DFS). Data were benchmarked.Results: After censoring patients undergoing minimalrisk surgery, 30 DM comprised 11 % for all patients, -8.1 % for patients after elective surgery and 8 % after R0-resection. 30 DM caused by surgical complications was 0.7 %, 0.8 % and 0.3 %, respectively, 30 DM caused by medical causes 10.3 % (cardiac in 5.1 %, pulmonary in 2.0 % and other causes in 3.2 ...

show abstract

Prognosis in the Cases With Renal Cell Carcinoma According to Clinical Parameters

Abstract: These results suggested that sex, age, symptom, tumor size, growing type, and stage were important prognostic factors in renal cell carcinoma.

Cited by 7 publications

References 0 publications

Treatment of childhood renal cell carcinoma with lymph node metastasis: Two cases and a review of literature

Treatment of childhood renal cell carcinoma with lymph node metastasis: Two cases and a review of literature

Lung Resistance-Related Protein

Is oncologic surgery in a low-volume district general hospital justified? A critical 24-year audit

Contact Info

Product

Resources

About